LunGuard

Company Overview

Snapshot

Founded in January 2009 by Ofer Pintel, LunGuard operated with 1–10 employees. LunGuard ceased operations in December 2020.

Business overview

LunGuard developed a proprietary physiological integrated patient interface system designed for ICU ventilated and tube-fed patients. Its core technology, the Reflux Prevention System (RPS), aimed to reduce Ventilator Associated Pneumonia (VAP) by managing reflux and preventing pulmonary aspiration. The system incorporated features such as intelligent reflux prevention, smart ETT cuff sealing monitoring, integrated pulmonary pressure detection, and PH sensors for reflux indication. This technology was designed to be compatible with any ventilator or feeding system, replacing traditional NG tubes with its own smart sensor, serving the global Health Tech & Life Sciences sector, specifically within Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

LunGuard ceased operations in December 2020, indicating a significant strategic shift and the conclusion of its development efforts in the medical device space. This event signals to investors that the company is no longer an active participant in the Health Tech & Life Sciences market.

Company Intelligence Q&A

What is LunGuard's primary focus?

LunGuard focuses on developing a proprietary physiological integrated patient interface system to prevent reflux in ventilated and tube-fed patients, aiming to reduce Ventilator Associated Pneumonia (VAP).

When was LunGuard founded?

LunGuard was founded in January 2009.

Who was a co-founder of LunGuard?

Ofer Pintel was a co-founder of LunGuard.

What was the status of LunGuard as of December 2020?

LunGuard ceased to operate in December 2020.

Which investors participated in LunGuard's funding round?

In January 2009, LunGuard received funding from investors including Maayan Ventures.